MAXAQUIN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Maxaquin, and when can generic versions of Maxaquin launch?

Maxaquin is a drug marketed by Pharmacia and is included in one NDA.

The generic ingredient in MAXAQUIN is lomefloxacin hydrochloride. There is one drug master file entry for this compound. Additional details are available on the lomefloxacin hydrochloride profile page.

Summary for MAXAQUIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	90
Patent Applications:	1,403
Formulation / Manufacturing:	see details
DailyMed Link:	MAXAQUIN at DailyMed

Drug patent expirations by year for MAXAQUIN

Anatomical Therapeutic Chemical (ATC) Classes for MAXAQUIN

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for MAXAQUIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia	MAXAQUIN	lomefloxacin hydrochloride	TABLET;ORAL	020013-001	Feb 21, 1992		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MAXAQUIN

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmacia	MAXAQUIN	lomefloxacin hydrochloride	TABLET;ORAL	020013-001	Feb 21, 1992	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MAXAQUIN

See the table below for patents covering MAXAQUIN around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
European Patent Office	0140116	A 6-FLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AND THE METHOD FOR PREPARING THE SAME	⤷ Try a Trial
Yugoslavia	160384		⤷ Try a Trial
Japan	S6256151		⤷ Try a Trial
Croatia	P930651	PROCESS FOR THE PREPARATION OF 6-FLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE	⤷ Try a Trial
South Korea	850002481		⤷ Try a Trial
Hong Kong	62191	A 6-FLUORO-1,4-DIHYDRO-4-OXO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AND THE METHOD FOR PREPARING THE SAME	⤷ Try a Trial
Croatia	P930652	PROCESS FOR THE PREPARATION OF 6-FLUORO-1,4-DIDYDRO-4-OYO-7-SUBSTITUTED PIPERAZINYL-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVE	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for MAXAQUIN

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0140116	SPC/GB93/020	United Kingdom	⤷ Try a Trial	SPC/GB93/020, EXPIRES: 20051212
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for MAXAQUIN

Anatomical Therapeutic Chemical (ATC) Classes for MAXAQUIN

Make Better Decisions: Try a trial or see plans & pricing